Paroxetine, a Selective Serotonin Reuptake Inhibitor, Reduces Depressive Symptoms and Subjective Handicaps in Patients with Dizziness
Paroxetine, a Selective Serotonin Reuptake Inhibitor, Reduces Depressive Symptoms and Subjective Handicaps in Patients with Dizziness
复制标题
帕罗西汀是一种选择性血清素再摄取抑制剂，可减轻头晕患者的抑郁症状和主观障碍
DOI：
10.1097/00129492-200407000-00022
复制
发表时间：
2004
影响因子：
2.1
通讯作者：
T. Kubo
中科院分区：
文献类型：
--
作者：
A. Horii;K. Mitani;T. Kitahara;A. Uno;N. Takeda;T. Kubo
目的和研究设计：在治疗眩晕患者时，无论是否存在明确的器质性疾病，都应仔细考虑精神病学方面的问题。在这项前瞻性研究中，我们旨在阐明帕罗西汀在治疗头晕中的作用，帕罗西汀是一种选择性的5-羟色胺再摄取抑制剂。地点和患者：47例主诉头晕的患者给予帕罗西汀20 mg/d治疗。采用Zung抑郁自评量表评定患者的抑郁状态。治疗结果通过使用头晕和不稳定问卷对日常生活中的主观障碍进行自我评估来衡量。该问卷包括五个与情绪或身体功能障碍有关的因素，这些因素可能会受到头晕的影响。在帕罗西汀治疗4周和8周后评估抑郁自评量表评分和主观障碍的变化。结果：在有明确器质性疾病且抑郁自评量表得分较高的患者中，帕罗西汀改善了所有五个主观障碍因素和抑郁自评量表得分。抑郁自评量表得分的下降与主观障碍的改善显著相关，主观障碍的改善与情绪问题有关，而与身体功能障碍的因素无关。帕罗西汀对无器质性疾病但抑郁自评量表得分高的患者的情绪问题相关因素和抑郁自评量表得分的改善也是有效的。在有无器质性疾病且抑郁自评量表得分低的患者中，帕罗西汀对任何主观障碍因素和抑郁自评量表得分均无影响。结论：帕罗西汀在治疗头晕患者时，能有效缓解头晕所致的主观障碍，尤其是对抑郁自评量表评分较高的患者。
Objective and Study Design: When treating dizzy patients, the psychiatric aspect should be carefully addressed regardless of whether a well-defined organic disease is present. In this prospective study, we aimed to elucidate the role of paroxetine, a selective serotonin reuptake inhibitor, in the treatment of dizziness. Setting and Patients: Forty-seven patients who complained of dizziness were treated with 20 mg of paroxetine per day. The depressive state of the patient was evaluated by the Zung Self-Rating Depression Scale (SDS). Treatment outcomes were measured with self-assessment of subjective handicaps in daily life using a dizziness and unsteadiness questionnaire. The questionnaire consisted of five factors related to emotional or bodily dysfunction that could be affected by dizziness. Changes in Self-Rating Depression Scale scores and subjective handicaps were assessed at 4 and 8 weeks after the start of paroxetine. Results: In patients having well-defined organic diseases with high Self-Rating Depression Scale scores, paroxetine improved all five subjective handicap factors as well as Self-Rating Depression Scale scores. The decline in Self-Rating Depression Scale scores showed a significant correlation with improvement of subjective handicaps, which was related to emotional problems but not factors related to bodily dysfunction. Paroxetine was also effective for an improvement of factors related to emotional problems and Self-Rating Depression Scale scores in patients not having organic diseases but with high Self-Rating Depression Scale scores. In patients either with or without organic diseases with low Self-Rating Depression Scale scores, paroxetine had no effect on any subjective handicap factors and Self-Rating Depression Scale scores. Conclusion: In the treatment of dizzy patients, paroxetine was effective at relieving subjective handicaps caused by dizziness, specifically, in patients with high Self-Rating Depression Scale scores.